AIM Vaccine Co., Ltd. Class H (HK:6660) has released an update.
AIM Vaccine Co., Ltd. has secured clinical trial approval for its mRNA-based RSV vaccine, developed by its subsidiary Liverna Therapeutics Inc. This marks a significant step forward for the company, as RSV remains a major health concern with no approved vaccines in China. The approval positions AIM Vaccine as a leader in China’s mRNA vaccine space, with potential for substantial market growth.
For further insights into HK:6660 stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
